Cargando…

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients

BACKGROUND: Luteinizing hormone-releasing hormone (LH-RH) agonists are the standard for androgen deprivation therapy (ADT) in prostate cancer (PCa) patients. Current guidelines recommend serum testosterone measurement to assess the efficacy of ADT and to define castration resistance. However, serum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morote, Juan, Comas, Imma, Ferrer, Roser, Planas, Jacques, Celma, Anna, Regis, Lucas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651562/ https://www.ncbi.nlm.nih.gov/pubmed/29058606 http://dx.doi.org/10.1186/s12929-017-0386-0

Ejemplares similares

Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration
por: Morote, Juan, et al.
Publicado: (2020)

Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer
por: Koh, Yoko, et al.
Publicado: (2020)

Definition of Castrate Resistant Prostate Cancer: New Insights
por: Morote, Juan, et al.
Publicado: (2022)

Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness
por: Morote, Juan, et al.
Publicado: (2014)

Serum oestradiol-17 beta, testosterone, luteinizing hormone and follicle-stimulating hormone in males with breast cancer.
por: Ribeiro, G. G., et al.
Publicado: (1980)

Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
por: Triquell, Marina, et al.
Publicado: (2022)

Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
por: Angulo, J. C., et al.
Publicado: (2022)

Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy
por: Triquell, Marina, et al.
Publicado: (2022)

The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review
por: Aguilar, Adriana, et al.
Publicado: (2023)

Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review
por: Cuadras, Mercè, et al.
Publicado: (2022)

Association of Serum Testosterone and Luteinizing Hormone With Blood Pressure and Risk of Cardiovascular Disease in Middle‐Aged and Elderly Men
por: Qu, Mengyuan, et al.
Publicado: (2021)

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category
por: Morote, Juan, et al.
Publicado: (2022)

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014)

The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited
por: Oduwole, Olayiwola O., et al.
Publicado: (2021)

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome
por: Chun, Sungwook
Publicado: (2014)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand
por: Morote, Juan, et al.
Publicado: (2022)

SAT-LB1 Detection of Serum Macro-Luteinizing Hormone
por: Ogura-Ochi, Kanako, et al.
Publicado: (2020)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

Serum testosterone and dihydrotestosterone in carcinoma of the prostate.
por: Ghanadian, R., et al.
Publicado: (1979)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
por: Sakamoto, Shinichi, et al.
Publicado: (2019)

Serum Testosterone Level, Testosterone Replacement Treatment, and Prostate Cancer
por: Atan, Ali, et al.
Publicado: (2013)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
por: Cánovas, Verónica, et al.
Publicado: (2017)

Bladder Cancer in an Inguinoscrotal Vesical Hernia
por: Regis, Lucas, et al.
Publicado: (2012)

Normal Testosterone but Higher Luteinizing Hormone Plasma Levels in Men With Hypersexual Disorder
por: Chatzittofis, Andreas, et al.
Publicado: (2020)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

Basal serum luteinizing hormone value as the screening biomarker in female central precocious puberty
por: Heo, Seung, et al.
Publicado: (2019)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
por: Lam, Hung-Ming, et al.
Publicado: (2018)

“Prostate telocytes change their phenotype in response to castration or testosterone replacement”
por: Felisbino, Sérgio Luis, et al.
Publicado: (2019)

Correlation between the Serum Luteinizing Hormone to Folliclestimulating Hormone Ratio and the Anti-Müllerian Hormone Levels in Normo-ovulatory Women
por: Lee, Jong Eun, et al.
Publicado: (2015)

Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen
por: Pastuszak, Alexander W, et al.
Publicado: (2015)

Effect of short-term fattening period and castration method on productivity, serum testosterone, and economic efficacy in Hanwoo cattle
por: Ahn, Jun Sang, et al.
Publicado: (2023)

Egg deposition of maternal testosterone is primarily controlled by the preovulatory peak of luteinizing hormone in Japanese quail
por: Okuliarova, Monika, et al.
Publicado: (2018)

Serum testosterone levels are positively associated with serum anti-mullerian hormone levels in infertile women
por: Lin, Li-Te, et al.
Publicado: (2021)

Associations of Serum Follicle-Stimulating Hormone and Luteinizing Hormone Levels with Fat and Lean Mass during Menopausal Transition
por: Liu, Xun, et al.
Publicado: (2022)

Serum Lutein is related to Relational Memory Performance
por: Cannavale, Corinne N., et al.
Publicado: (2019)

Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines
por: Olivan, M., et al.
Publicado: (2015)

Effect of Varicocelectomy on Serum Follicle-Stimulating Hormone and Testosterone; The Interrelationship Between Hormonal Variables
por: Alfozan, Mohammed
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_26up8vd4hihmi2mvbijnv2use6